BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia

Yulin Li, Anja Deutzmann, Peter S. Choi, Alice C. Fan, Dean W. Felsher

    Research output: Contribution to journalArticlepeer-review

    15 Scopus citations

    Abstract

    Oncogene inactivation in both clinical targeted therapies and conditional transgenic mouse cancer models can induce significant tumor regression associated with the robust induction of apoptosis. Here we report that in MYC-, RAS-, and BCR-ABL-induced acute lymphoblastic leukemia (ALL), apoptosis upon oncogene inactivation is mediated by the same pro-apoptotic protein, BIM. The induction of BIM in the MYC-and RAS-driven leukemia is mediated by the downregulation of miR-17-92. Overexpression of miR-17-92 blocked the induction of apoptosis upon oncogene inactivation in the MYC and RAS-driven but not in the BCR-ABL-driven ALL leukemia. Hence, our results provide novel insight into the mechanism of apoptosis upon oncogene inactivation and suggest that induction of BIM-mediated apoptosis may be an important therapeutic approach for ALL.

    Original languageEnglish (US)
    Pages (from-to)26926-26934
    Number of pages9
    JournalOncotarget
    Volume7
    Issue number19
    DOIs
    StatePublished - May 10 2016

    Keywords

    • Apoptosis
    • BIM
    • Oncogene inactivation
    • Targeted therapies

    ASJC Scopus subject areas

    • Oncology

    Fingerprint

    Dive into the research topics of 'BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia'. Together they form a unique fingerprint.

    Cite this